SICHUAN HUIYU PHARMACEUTICAL CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 13.19 CNY | +0.38% |
|
-4.42% | -12.82% |
| May. 15 | China Grants Drug Registration for Huiyu Pharma's Two Injectables | MT |
| Apr. 26 | Sichuan Huiyu Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| Sales 2022 | 1.49B 206M | Sales 2023 | 927M 128M | Capitalization | 6.41B 884M |
|---|---|---|---|---|---|
| Net income 2022 | 249M 34.33M | Net income 2023 | 140M 19.3M | EV / Sales 2022 | 2.73 x |
| Net cash position 2022 | 2.53B 348M | Net cash position 2023 | 2.14B 295M | EV / Sales 2023 | 4.6 x |
| P/E ratio 2022 |
26.4
x | P/E ratio 2023 |
45.8
x | Employees | 1,364 |
| Yield 2022 |
1.51% | Yield 2023 |
1.41% | Free-Float | 39.27% |
More Fundamentals
* Assessed data
More news
| 1 day | +0.38% | ||
| 1 week | -4.42% | ||
| Current month | -7.37% | ||
| 1 month | -8.28% | ||
| 3 months | +2.65% | ||
| 6 months | -17.46% | ||
| Current year | -12.82% |
1 week
13.03
13.78
1 month
13.0314.67
Current year
9.4515.42
1 year
9.4517.12
3 years
9.4542.59
5 years
9.4542.59
10 years
9.4542.59
| Managers | Title | Age | Since |
|---|---|---|---|
Zhao Ding
CEO | Chief Executive Officer | 39 | 10-10-11 |
Lan Gao
DFI | Director of Finance/CFO | 53 | 19-10-13 |
Li Na Ma
BRD | Director/Board Member | 48 | 22-04-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Li Na Ma
BRD | Director/Board Member | 48 | 22-04-30 |
Lan Gao
DFI | Director of Finance/CFO | 53 | 19-10-13 |
Zhao Ding
CEO | Chief Executive Officer | 39 | 10-10-11 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-07 | 13.19 | +0.38% | 802,840 |
| 24-06-06 | 13.14 | -2.74% | 1,718,365 |
| 24-06-05 | 13.51 | -0.22% | 1,171,414 |
| 24-06-04 | 13.54 | -1.88% | 1,329,915 |
End-of-day quote Shanghai S.E., June 06, 2024
More quotes
Sichuan Huiyu Pharmaceutical Co Ltd is a China-based company principally engaged in the research and development, production and sales of anti-tumor and injection drugs. The Companyâs products are mainly anti-tumor chemical injections, including pemetrexed disodium for injection, docetaxel injection, zoledronic acid injection, irinotecan hydrochloride injection, doxorubicin hydrochloride injection liquid and azacitidine for injection. The Company's products are mainly used in the clinical treatment of various adaptive diseases. The Company distributes its products both in the domestic market and to overseas markets.
Sector
Pharmaceuticals
Calendar
2024-08-22
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -12.82% | 771M | |
| +48.39% | 779B | |
| -6.13% | 354B | |
| +20.61% | 333B | |
| +10.00% | 301B | |
| +18.87% | 249B | |
| -1.96% | 216B | |
| +11.11% | 214B | |
| +5.80% | 163B | |
| -2.50% | 159B |
- Stock Market
- Equities
- 688553 Stock
